Post Conference Perspective: Immune Checkpoint Inhibitors in Advanced and Metastatic Urothelial Carcinoma - Episode 8
Petros Grivas, MD, PhD, shares his thoughts on the future of maintenance therapy in locally advanced or metastatic urothelial carcinoma.
Petros Grivas, MD, PhD: When it comes to this particular question of what to do in frontline settings, there has been a worldwide adoption, of the switch-maintenance immunotherapy with avelumab after platinum-based chemotherapy in those who achieve response or stable disease. This is going to dominate the frontline setting, and obviously we are going to report quality of life, patient outcomes, manuscripts, biomarker manuscripts, and subsequent analyses, and we’ll have presented some of that data at ESMO [European Society for Medical Oncology Congress] and other meetings.
It is interesting, in the future, to see whether avelumab by itself stays, or if combinations to build on avelumab switch maintenance become more prevalent. Future trials are going to ask these questions about combination therapies but can also be interesting to look at in the maintenance setting.
Transcript edited for clarity.